FDA panel votes against changes to Aleve labels

By WEEK Producer

February 11, 2014 Updated Feb 11, 2014 at 8:33 PM CDT

An FDA panel voted Tuesday against changing the labels on Naproxen, sold as Aleve.

Members said there is not enough evidence to prove the painkiller is safer for heart patients than other similar products.

Millions of Americans take the medication to control pain and arthritis.

All other pain killers like ibuprofen have labels warning of the potential for increased heart risks.

To submit a comment on this article, your email address is required. We respect your privacy and your email will not be visible to others nor will it be added to any email lists.